Two Cases of Interstitial Pneumonitis Caused by Rituximab Therapy
Rituximab, a chimeric monoclonal antibody directed against CD20, has become a part of the standard therapy for patients with non-Hodgkin's lymphoma either in combination with other drugs or as a single agent. The CD20 antigen is expressed on 95% of B-cell lymphoma cells and normal B-cells but,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
The Korean Association of Internal Medicine
2006
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890722/ |